383 related articles for article (PubMed ID: 16751138)
21. Seminal Factor VIII and von Willebrand Factor: a possible role of the conventional clotting system in human semen?
Lwaleed BA; Greenfield R; Royle E; Birch B; Cooper AJ
Int J Androl; 2005 Feb; 28(1):31-8. PubMed ID: 15679619
[TBL] [Abstract][Full Text] [Related]
22. Oncotic, hemodilutional, and hemostatic effects of isotonic saline and hydroxyethyl starch solutions in clinically normal ponies.
Jones PA; Tomasic M; Gentry PA
Am J Vet Res; 1997 May; 58(5):541-8. PubMed ID: 9140565
[TBL] [Abstract][Full Text] [Related]
23. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
24. Analysis of prolonged storage on coagulation Factor (F)V, FVII, and FVIII in thawed plasma: is it time to extend the expiration date beyond 5 days?
Tholpady A; Monson J; Radovancevic R; Klein K; Bracey A
Transfusion; 2013 Mar; 53(3):645-50. PubMed ID: 22803679
[TBL] [Abstract][Full Text] [Related]
25. Effect of temperature on plasma freezing under industrial conditions.
Bravo MI; Grancha S; Jorquera JI
Pharmeur Sci Notes; 2006 Aug; 2006(1):31-5. PubMed ID: 17694644
[TBL] [Abstract][Full Text] [Related]
26. Study of coagulation factor activities in apheresed thawed fresh frozen plasma at 1-6 degrees C for five days.
Sidhu RS; Le T; Brimhall B; Thompson H
J Clin Apher; 2006 Dec; 21(4):224-6. PubMed ID: 16607628
[TBL] [Abstract][Full Text] [Related]
27. Haemostatic changes and acquired activated protein C resistance in normal pregnancy.
Mahieu B; Jacobs N; Mahieu S; Naelaerts K; Vertessen F; Weyler J; Jacquemyn Y; Van der Planken M
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):685-8. PubMed ID: 17890957
[TBL] [Abstract][Full Text] [Related]
28. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
29. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
[TBL] [Abstract][Full Text] [Related]
30. Storage of thawed cryoprecipitated AHF is better at room temperature than at 1 degree C to 6 degrees C for factor VIII content.
Saxena S; Odono V; Francis R; Shulman IA
Arch Pathol Lab Med; 1991 Apr; 115(4):343-5. PubMed ID: 1901483
[TBL] [Abstract][Full Text] [Related]
31. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
32. Effect of freezing method and storage at -20 degrees C and -70 degrees C on prothrombin time, aPTT and plasma fibrinogen levels.
Alesci S; Borggrefe M; Dempfle CE
Thromb Res; 2009 May; 124(1):121-6. PubMed ID: 19128820
[TBL] [Abstract][Full Text] [Related]
33. Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women.
Ay C; Thom K; Abu-Hamdeh F; Horvath B; Quehenberger P; Male C; Mannhalter C; Pabinger I
Haemophilia; 2010 Jan; 16(1):111-7. PubMed ID: 19758307
[TBL] [Abstract][Full Text] [Related]
34. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
[TBL] [Abstract][Full Text] [Related]
35. Storage of thawed plasma for a liquid plasma bank: impact of temperature and methylene blue pathogen inactivation.
Thiele T; Kellner S; Hron G; Wasner C; Nauck M; Zimmermann K; Wessel A; Warkentin TE; Greinacher A; Selleng K
Transfusion; 2012 Mar; 52(3):529-36. PubMed ID: 21880044
[TBL] [Abstract][Full Text] [Related]
36. Effect of plasma freezing temperature, anticoagulant and time of storage on factor VIII:C activity in cryoprecipitate.
Piedras J; Sánchez-Montero PE; Herrera FM; Córdova MS; Sánchez-Medal L
Arch Med Res; 1993; 24(1):23-6. PubMed ID: 8292873
[TBL] [Abstract][Full Text] [Related]
37. Warm storage of whole blood for 72 hours.
Hughes JD; Macdonald VW; Hess JR
Transfusion; 2007 Nov; 47(11):2050-6. PubMed ID: 17958534
[TBL] [Abstract][Full Text] [Related]
38. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
39. Thrombin generation and clot formation in methylene blue-treated plasma and cryoprecipitate.
Cardigan R; Philpot K; Cookson P; Luddington R
Transfusion; 2009 Apr; 49(4):696-703. PubMed ID: 19170989
[TBL] [Abstract][Full Text] [Related]
40. Coagulation profile of liquid-state plasma.
Gosselin RC; Marshall C; Dwyre DM; Gresens C; Davis D; Scherer L; Taylor D
Transfusion; 2013 Mar; 53(3):579-90. PubMed ID: 22844966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
